Federal contractor · public award history
LOVELACE BIOMEDICAL RESEARCH INSTITUTE
Parent: LOVELACE BIOMEDICAL RESEARCH INSTITUTE MBT9RXJJ7428
- Awards we know about
- 28
- Typical size
- $1.14M
- Middle of their public awards
- Dollars on those awards
- $85.80M
Most of their awards we can see fall roughly between $233,476 and $2.20M.
From official USAspending contract records — not a capability rating, past-performance score, or recommendation to team or bid.
Public award activity by year
Sum of award values in our USAspending index (not a full financial history).
- 2024$5.41M
- 2025$80.39M
Awarding agencies
- Department of Health and Human Services (28)
Industries & product codes
Award history
- Department of Health and Human Services$10,000
EVALUATION AND TESTING SERVICES (ETS) FOR VACCINES AND OTHER BIOLOGICS FOR INFECTIOUS DISEASES.
- Department of Health and Human Services$5.76M
RADNUC 2201: PERFORMANCE VERIFICATION OF INSTITUTIONAL RADIATION DOSE RESPONSE FOR ACUTE RADIATION SYNDROME (ARS) ANIMAL MODELS (RODENT, RABBIT, MINIPIG, OR NON-HUMAN PRIMATE [NHP])
- Department of Health and Human Services$7.06M
SOLE SOURCE AWARD OF A 24-MONTH PERIOD, FIRM FIXED PRICE (FFP), ENDS TOXICOLOGICAL STUDIES FOR CENTER FOR TOBACCO PRODUCTS (CTP).
- Department of Health and Human Services$625,408
THE CONTRACTOR SHALL PERFORM THE TRANSFER, VALIDATION AND QUALIFICATION OF BIOANALYTICAL METHODS FOR DETECTION OF CABOTEGRAVIR AND LEVONORGESTREL IN RAT AND NONHUMAN PRIMATE PLASMA
- Department of Health and Human Services$78,695
BIO-AMT-2301: IDIQ CONTRACT MANAGEMENT SUPPORT ACTIVITIES
- Department of Health and Human Services$75,000
LOVELACE BIOMEDICAL RESEARCH INSTITUTE(CHEM) - IDIQ FOR BARDA CRN ANIMAL MODEL DEVELOPMENT
- Department of Health and Human Services$46.05M
STUDY OF E-CIGARETTE AEROSOL TOXICITY IN IN VIVO NONCLINICAL MODELS.
- Department of Health and Human Services$255,825
TRANSFER AND VALIDATION OF BIOANALYTICAL METHOD FOR DETECTION OF CABOTEGRAVIR IN RAT PLASMA
- Department of Health and Human Services$625,344
GTRP: PHARMACOLOGY/TOXICOLOGY CORE LABORATORY PROJECT FOR RSA NO. 2034
- Department of Health and Human Services$1.61M
GENE THERAPY RESOURCE PROGRAM (GTRP): PHARMACOLOGY/TOXICOLOGY CORE LABORATORY - SCIENTIFIC PROJECT FOR RSA NO. 2057 (RADER)
- Department of Health and Human Services$1.14M
GENE THERAPY RESOURCE PROGRAM (GTRP): PHARMACOLOGY AND TOXICOLOGY CORE LABORATORY
- Department of Health and Human Services$4.02M
NON-CLINICAL SAFETY ASSESSMENT OF GENE THERAPY (PCCA, MMAB, DOK7 AND COLQ) TO SUPPORT PLATFORM GENE THERAPY FOR CONGENITAL MYASTHENIC DISEASES (DOK7, COLQ) AND ACIDEMIA (PCCA, MMAB)
- Department of Health and Human Services$507,703
THE NHLBI REQUIRES THE GENE THERAPY RESOURCE PROGRAM (GTRP) SUPPORT TRANSLATIONAL GENE THERAPY RESEARCH BY PROVIDING RESOURCES AND SERVICES FROM THREE CORE LABORATORIES: 1.) PHARMACOLOGY AND TOXICOLOGY CORE LABORATORY, 2.) PRECLINICAL VECTOR CORE LABORATORY, 3.) CLINICAL COORDINATING CENTER (CCC), WHICH IS NOT REQUIRED TO HAVE ANY LABORATORY CAPABILITIES.
- Department of Health and Human Services$366,923
EFFICACY AND SAFETY EVALUATION OF A LEAD GENE THERAPY CANDIDATE IN METHYL MELANOMIC ACIDEMIA (MMAB) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT.
- Department of Health and Human Services$2.27M
EFFICACY AND SAFETY EVALUATION OF A LEAD GENE THERAPY CANDIDATE IN PROPIONIC ACIDEMIA (PA) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT. PERIOD OF PERFORMANCE SEPTEMBER 25, 2020 - SEPTEMBER 24, 2022
- Department of Health and Human Services$140,848
EVALUATION OF POTENTIAL RESPIRATORY STIMULANT. TO4. PERIOD OF PERFORMANCE: MARCH 21, 2024 - MARCH 20, 2025.
- Department of Health and Human Services$2.33M
CHARACTERIZATION OF A NON-ADDICTIVE SMALL MOLECULE THERAPEUTICS FOR THE MANAGEMENT OF NON-CANCER PAIN PERIOD OF PERFORMANCE SEPTEMBER 18, 2020 - SEPTEMBER 17, 2022
- Department of Health and Human Services$4,000
CRO SUPPORT FOR NCATS MEDICINAL CHEMISTRY FOR LEAD OPTIMIZATION.
- Department of Health and Human Services$211,128
RESPIRATORY INTERACTION STUDIES IN RODENTS, ABILITY OF A TEST ARTICLE TO REVERSE THE RESPIRATORY DEPRESSANT EFFECTS OF OPIOIDS. TO5. PERIOD OF PERFORMANCE: MARCH 21, 2024 - MARCH 20, 2025.
- Department of Health and Human Services$3.87M
TASK ORDER 1 -TITLE: ARE REDUCTIONS IN BOE, BOPH, AND OTHER HEALTH RISK MARKERS PROPORTIONAL TO REDUCTIONS IN CIGARETTE SMOKING UPON SWITCHING TO ENDS
- Department of Health and Human Services$1.25M
TASK ORDER 2 - EXAMINING THE INFLUENCE OF SYNTHETIC COOLING AGENTS ON CIGARETTE SENSORY AND SUBJECTIVE EFFECTS AND USE BEHAVIOR
- Department of Health and Human Services$2.13M
CTP-2022-111127 - SALTS
- Department of Health and Human Services$792,052
BIOANALYTICAL SUPPORTS FOR A GLP TOX/BIODISTRIBUTION STUDY IN MINI-PIGS
- Department of Health and Human Services$2.01M
NATURAL HISTORY STUDIES IN NEUROMUSCULAR JUNCTION (NMJ) DISEASE MOUSE MODELS. PERIOD OF PERFORMANCE SEPTEMBER 28, 2020 - DECEMBER 31, 2021
- Department of Health and Human Services$1.32M
CHARACTERIZATION OF A DOWNSTREAM GENE THERAPEUTIC FOR THE REPARATIVE TREATMENT OF SEVERE FRACTURES PERIOD OF PERFORMANCE SEPTEMBER 24, 2020 - NOVEMBER 23, 2021
- Department of Health and Human Services—
EO14042 - THE CONTRACTOR SHALL PROVIDE PRECLINICAL DEVELOPMENT SUPPORT FOR CANDIDATE PRODUCTS AND DRUG DEVELOPMENT ACTIVITIES.
- Department of Health and Human Services$1,694
TASK ORDER ENTITLED, "PHARMACODYNAMICS OF THE MAS-RELATED GENE X2 (MRGX2) ANTAGONIST SYR268215 IN THE HUMANIZED MRGX2 KNOCK-IN (KI) MOUSE."
- Department of Health and Human Services$1.28M
CHARACTERIZATION OF A NON-PARALYZING BONT-BASED BIOPHARMACEUTICAL FOR THE TREATMENT OF NEUROPATHIC PAIN
Intelligence only — not legal advice, not a past-performance evaluation, and not a recommendation to team or bid. Verify on USAspending and SAM.gov.